<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In 2008, the WHO combined the former categories <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RCMD</z:e> (refractory cytopenia with multilineage <z:mpath ids='MPATH_589'>dysplasia</z:mpath>) and <z:e sem="disease" ids="C1301356" disease_type="Neoplastic Process" abbrv="">RCMD-RS</z:e> (ring sideroblasts â‰¥ 15%) </plain></SENT>
<SENT sid="1" pm="."><plain>We studied the clinical impact and genetic background of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RCMD</z:e>, and <z:e sem="disease" ids="C1301356" disease_type="Neoplastic Process" abbrv="">RCMD-RS</z:e> in 1082 patients </plain></SENT>
<SENT sid="2" pm="."><plain>Good karyotypes (IPSS) were similarly frequent in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RCMD</z:e>, and <z:e sem="disease" ids="C1301356" disease_type="Neoplastic Process" abbrv="">RCMD-RS</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>2-year overall survival (OS) rates were similar in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RARS</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RCMD</z:e>, and <z:e sem="disease" ids="C1301356" disease_type="Neoplastic Process" abbrv="">RCMD-RS</z:e> (85.9%/89.0%/91.7%; n.s.) </plain></SENT>
<SENT sid="4" pm="."><plain>The 2-year OS rate was better in good than intermediate or poor karyotypes (p&lt;0.001) </plain></SENT>
<SENT sid="5" pm="."><plain>These results support to combine <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RCMD</z:e> and <z:e sem="disease" ids="C1301356" disease_type="Neoplastic Process" abbrv="">RCMD-RS</z:e> as performed by WHO and emphasize the prognostic power of cytogenetic criteria for these <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> subtypes </plain></SENT>
</text></document>